|Day Low/High||79.22 / 85.77|
|52 Wk Low/High||16.12 / 105.00|
Several sessions over the past 10 days have seen increased trading volume at the NYSE, but not the Nasdaq, and for the S&P 500, but not the Nasdaq Composite. Is this professional risk reduction?
Investors are chasing every name that's developing a promising coronavirus vaccine. These stocks will be winners no matter which companies are successful.
Covid itself, and therapeutics or vaccines associated with taking on the SARS-CoV-2 coronavirus, is under a public microscope.
One day after deciding that we still could not confirm the market's uptrend, we are forced to ask the opposite.
Make sure that your portfolio is composed of sane assets for the balance of this crazy year.
Electoral risk remains the monster under the bed, and it only grows as our legislators intentionally choose the blame game over honest cooperation.
This writer is rooting for the success of all efforts to halt the spread of the virus as he struggles with the aftereffects of the disease.
Plus, picking up dinged shares among Thursday's wreckage in the tech sector.
Plus, reading tea leaves in the recent action in Apple and Salesforce.com.
Plus, Veeva Systems reports stellar results and ups its guidance.
Here's my 'counterintuitive' bet on lower Treasury prices, and therefore higher rates, right now.
Monday's market action was in no way similar to that recent disparity between the 'haves' and 'have nots.'
The equity market recovery is just as sloppy in performance as the economy itself.
The headline numbers don't present the full story of what is going on with the equity markets.
Plus, quick looks at Joe Biden's VP choice, the latest on the Covid-19 vaccine front and Tesla's stock split.
Markets may believe that we are closer to the effective use of vaccines and therapeutics than we know in this battle against Covid-19.
Our fate is in the hands of a few dozen companies with a dizzying array of clinical trials, and whoever gets there first is gonna make a fortune.
If you are out of step with the marketplace, do not blame the marketplace. Understand that you have failed to adapt.
The extent of the measures taken to combat the virus seem to be an overreaction, and no one should count on a vaccine being a magic bullet.
What if the market is simply pricing in a quarter that had already been priced out?
Equity markets had a tougher day on Wednesday than immediately meets the eye. And did you catch what Trump said?
I would wait until the next down day, and there will be one.
WDAY looks ready to break out as traders weigh wether markets are now overbought after this 2-day run.
PFE is collaborating with German drugmaker BioNTech in the effort to find a well tolerated, effective vaccine.
Here again is my approach and my three stock groups: 'rebound', 'revenue' and 'virus'.
I am pretty well covered in my 'virus group'. I could definitely see bringing a few shares of REGN on board the next time the algorithms include that name in a broad selloff. Not before.
When the central bank is on top of their game as they have been of late, credit must go where credit is due.